Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics


Amneal Pharmaceuticals, Inc. (AMRX): $3.36

0.18 (+5.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AMRX POWR Grades


  • AMRX scores best on the Value dimension, with a Value rank ahead of 99.91% of US stocks.
  • The strongest trend for AMRX is in Momentum, which has been heading down over the past 179 days.
  • AMRX ranks lowest in Momentum; there it ranks in the 8th percentile.

AMRX Stock Summary

  • With a one year PEG ratio of 624.62, Amneal Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.48% of US stocks.
  • AMRX's current price/earnings ratio is 119.78, which is higher than 94.79% of US stocks with positive earnings.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 11.52 for Amneal Pharmaceuticals Inc; that's greater than it is for 94.31% of US stocks.
  • Stocks that are quantitatively similar to AMRX, based on their financial statements, market capitalization, and price volatility, are MAXN, VJET, LEDS, ALSN, and DGII.
  • Visit AMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.amneal.com.

AMRX Valuation Summary

  • AMRX's price/earnings ratio is 184.3; this is 404.93% higher than that of the median Healthcare stock.
  • Over the past 42 months, AMRX's EV/EBIT ratio has gone up 2.3.
  • AMRX's price/sales ratio has moved down 4.9 over the prior 42 months.

Below are key valuation metrics over time for AMRX.

Stock Date P/S P/B P/E EV/EBIT
AMRX 2021-08-31 0.8 4.9 184.3 28.7
AMRX 2021-08-30 0.8 4.6 171.5 27.9
AMRX 2021-08-27 0.8 4.6 172.8 28.0
AMRX 2021-08-26 0.8 4.5 169.2 27.7
AMRX 2021-08-25 0.8 4.8 181.3 28.5
AMRX 2021-08-24 0.8 4.8 181.0 28.5

AMRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRX has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
  • AMRX's asset turnover comes in at 0.514 -- ranking 77th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AMRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.514 0.343 0.037
2021-03-31 0.495 0.320 0.031
2020-12-31 0.483 0.315 0.032
2020-09-30 0.466 0.304 0.028
2020-06-30 0.440 0.283 0.063
2020-03-31 0.419 0.270 0.060

AMRX Stock Price Chart Interactive Chart >

Price chart for AMRX

AMRX Price/Volume Stats

Current price $3.36 52-week high $5.99
Prev. close $3.18 52-week low $2.90
Day low $3.12 Volume 544,400
Day high $3.38 Avg. volume 693,020
50-day MA $3.46 Dividend yield N/A
200-day MA $4.39 Market Cap 1.02B

Amneal Pharmaceuticals, Inc. (AMRX) Company Bio


Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.


AMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

AMRX Latest Social Stream


Loading social stream, please wait...

View Full AMRX Social Stream

Latest AMRX News From Around the Web

Below are the latest news stories about Amneal Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMRX as an investment opportunity.

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

Amneal Expands Injectables Portfolio with 4 New Products

BRIDGEWATER, N.J., February 17, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the approval of four generic injectables products. Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethasone and azacitidine are bo

Yahoo | February 17, 2022

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

Yahoo | February 4, 2022

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

BRIDGEWATER, N.J., February 04, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022.

Yahoo | February 4, 2022

Shareholders in Amneal Pharmaceuticals (NYSE:AMRX) are in the red if they invested three years ago

Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...

Yahoo | February 2, 2022

Read More 'AMRX' Stories Here

AMRX Price Returns

1-mo -3.72%
3-mo -17.85%
6-mo -26.96%
1-year N/A
3-year -49.55%
5-year -79.07%
YTD -29.85%
2021 4.81%
2020 -5.19%
2019 -64.38%
2018 -18.74%
2017 25.66%

Continue Researching AMRX

Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:

Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5264 seconds.